Cleo Diagnostics (ASX.COV) Marks Ovarian Cancer Awareness Month

Cleo Diagnostics Limited (ASX.COV)

Cleo Diagnostics Marks Ovarian Cancer Awareness Month, Reinforcing its Commitment to Earlier Detection

Cleo Diagnostics (ASX: COV) is recognising Ovarian Cancer Awareness Month this February, highlighting the urgent and unmet clinical need for earlier and more accurate detection of ovarian cancer.

Ovarian cancer remains one of the most challenging cancers to diagnose early, with symptoms often vague, non-specific and easily overlooked. Critically, no diagnostic test exists today with diagnosis only confirmed after invasive surgery. As a result, a significant proportion of cases are diagnosed at advanced stages, where treatment options are more limited and survival outcomes are poorer. The stark fact is that 51% of women continue to die within 5 years of an Ovarian Cancer diagnosis, that’s over 6 times higher than with breast cancer at 8%.

Cleo Diagnostics is focused on addressing this challenge with its simple blood test designed to support earlier assessment and improve outcomes for all women. The Company’s test is underpinned by strong scientific evidence built over 15 years of R&D led by the discovery of novel biomarker CXCL10 which delivers superior performance to the existing standard of care. Cleo is close to bringing the test to its first U.S. patient market with an FDA submission anticipated later this year.

Commenting on Ovarian Cancer Awareness Month, Cleo Diagnostics’ Head of Corporate Development, Dayna Louca, said:

“Ovarian Cancer Awareness Month is an important reminder of how difficult this disease is to detect early and why continued investment in better diagnostics is critical as we have seen with other cancers.

We believe that Cleo’s ovarian cancer blood test has the potential to transform the landscape of ovarian cancer detection globally, and importantly drive positive health outcomes for all women.”

Throughout February, Cleo Diagnostics will participate in awareness-focused initiatives aimed at supporting education and engagement around ovarian cancer, while continuing to progress the commercialisation of its much-needed technology.

More information can be found at the Company’s website cleodx.com

Dayna Louca
Head of Corporate Development
+61 409 581 972
[email protected]